Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
NG-641
i
Other names:
NG-641, bispecific anti-stromal T-SIGn virus, NG 641
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Akamis Bio
Drug class:
CD3 agonist, IFNα stimulant, FAP inhibitor, CXCL10 stimulant, CXCL9 stimulant
Related drugs:
‹
blinatumomab (52)
epcoritamab-bysp (11)
elranatamab-bcmm (8)
MGD006 (6)
BI 764532 (5)
SAR442257 (4)
AMG 757 (4)
AZD5863 (3)
CTIM-76 (3)
EX103 (3)
JNJ-5322 (3)
A-319 (2)
AMG 794 (2)
ASP2138 (2)
IMC-F106C (2)
mosunetuzumab-axgb (2)
NVG-111 (2)
SAR446309 (2)
talquetamab-tgvs (2)
teclistamab-cqyv (2)
CC-93269 (2)
IGM-2323 (2)
AMV564 (2)
CLN-978 (1)
glofitamab-gxbm (1)
GEN1047 (1)
HPN-217 (1)
ISB 1342 (1)
LNK101 (1)
MGD024 (1)
SAR443216 (1)
GNC-035 (1)
REGN1979 (1)
AMG 701 (1)
REGN4018 (1)
XmAb14045 (1)
JNJ-63898081 (1)
AMG 509 (1)
A-337 (0)
ABBV-184 (0)
ABBV-383 IV (0)
ADG138 (0)
AFM11 (0)
AMG 211 (0)
AMG 562 (0)
APVO436 (0)
ASP2074 (0)
AVC-001 (0)
AZD0486 (0)
BA1202 (0)
BC3448 (0)
BI 765049 (0)
BNT142 (0)
BS006 (0)
CBA-1535 (0)
CC-1 (0)
CC-3 (0)
CCW702 (0)
CD30 biAb-AATC (0)
CLN-049 (0)
CM350 (0)
CM355 (0)
CMG1A46 (0)
ERY974 (0)
TRBS07 (0)
F182112 (0)
GB261 (0)
GEM333 (0)
GEN1044 (0)
GEN3017 (0)
GNC-039 (0)
GNR-084 (0)
HBM7004 (0)
HPN536 (0)
IBI-389 (0)
IGM-2537 (0)
IGM-2644 (0)
IO-312 (0)
ISB 1302 (0)
ISB 2001 (0)
JNJ-6358 (0)
JNJ-63709178 (0)
JNJ-67571244 (0)
JNJ-8343 (0)
JNJ-8543 (0)
JNJ-8902 (0)
JS203 (0)
LBL-033 (0)
FBTA05 (0)
M701 (0)
M802 (0)
MBS314 (0)
MK-6070 (0)
MP0533 (0)
NGM936 (0)
NILK-2301 (0)
NILK-2501 (0)
NM28-2746 (0)
PF-06671008 (0)
PF-07062119 (0)
PF-07260437 (0)
PIT565 (0)
QLS31904 (0)
QLS31905 (0)
QLS32015 (0)
REGN5459 (0)
RG6007 (0)
RG6129 (0)
RG6232 (0)
RG6286 (0)
RG6353 (0)
RG6524 (0)
RGV004 (0)
catumaxomab (0)
SAIL66 (0)
SAR440234 (0)
TAK-186 (0)
TQB2825 (0)
TQB2934 (0)
UMG2-CD3 BTCE (0)
Undisclosed HER2Bi-armed ATC (0)
WVT078 (0)
XmAb968 (0)
Y150 (0)
ZG006 (0)
AMG 160 (0)
activated CIK and bispecific antibody (0)
activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)
ARB202 (0)
RG6160 (0)
RG7802 (0)
AMG 330 (0)
AMG 673 (0)
GNC-038 (0)
AMG 596 (0)
RG6234 (0)
AMG 910 (0)
huCD33-BsAb (0)
REGN5458 (0)
GD2xCD3 (0)
MGD009 (0)
AMG 420 (0)
XmAb13676 (0)
JNJ-8780 (0)
RG6194 (0)
AMG 110 (0)
MCLA-117 (0)
XmAb18087 (0)
AMG 199 (0)
pegylated interferon α -2a (3)
nadofaragene firadenovec-vncg (1)
interferon alfa 2b (0)
JZP898 (0)
recombinant interferon alfa-2a (0)
SAR441000 (0)
Autologous CD34+ enriched HSPCs expressing interferon-alpha 2 (0)
peginterferon-α-2b (0)
IGN002 (0)
TAK-573 (0)
AAA614 (2)
177Lu-DOTA-EB-FAPI (0)
177Lu-LNC1004 (0)
BI 765179 (0)
MP0310 (0)
MP0317 (0)
RG7827 (0)
SHR-7367 (0)
[177Lu]FAPI-46 (0)
RG7461 (0)
BXCL701 (0)
blinatumomab (52)
epcoritamab-bysp (11)
elranatamab-bcmm (8)
MGD006 (6)
BI 764532 (5)
SAR442257 (4)
AMG 757 (4)
AZD5863 (3)
CTIM-76 (3)
EX103 (3)
JNJ-5322 (3)
A-319 (2)
AMG 794 (2)
ASP2138 (2)
IMC-F106C (2)
mosunetuzumab-axgb (2)
NVG-111 (2)
SAR446309 (2)
talquetamab-tgvs (2)
teclistamab-cqyv (2)
CC-93269 (2)
IGM-2323 (2)
AMV564 (2)
CLN-978 (1)
glofitamab-gxbm (1)
GEN1047 (1)
HPN-217 (1)
ISB 1342 (1)
LNK101 (1)
MGD024 (1)
SAR443216 (1)
GNC-035 (1)
REGN1979 (1)
AMG 701 (1)
REGN4018 (1)
XmAb14045 (1)
JNJ-63898081 (1)
AMG 509 (1)
A-337 (0)
ABBV-184 (0)
ABBV-383 IV (0)
ADG138 (0)
AFM11 (0)
AMG 211 (0)
AMG 562 (0)
APVO436 (0)
ASP2074 (0)
AVC-001 (0)
AZD0486 (0)
BA1202 (0)
BC3448 (0)
BI 765049 (0)
BNT142 (0)
BS006 (0)
CBA-1535 (0)
CC-1 (0)
CC-3 (0)
CCW702 (0)
CD30 biAb-AATC (0)
CLN-049 (0)
CM350 (0)
CM355 (0)
CMG1A46 (0)
ERY974 (0)
TRBS07 (0)
F182112 (0)
GB261 (0)
GEM333 (0)
GEN1044 (0)
GEN3017 (0)
GNC-039 (0)
GNR-084 (0)
HBM7004 (0)
HPN536 (0)
IBI-389 (0)
IGM-2537 (0)
IGM-2644 (0)
IO-312 (0)
ISB 1302 (0)
ISB 2001 (0)
JNJ-6358 (0)
JNJ-63709178 (0)
JNJ-67571244 (0)
JNJ-8343 (0)
JNJ-8543 (0)
JNJ-8902 (0)
JS203 (0)
LBL-033 (0)
FBTA05 (0)
M701 (0)
M802 (0)
MBS314 (0)
MK-6070 (0)
MP0533 (0)
NGM936 (0)
NILK-2301 (0)
NILK-2501 (0)
NM28-2746 (0)
PF-06671008 (0)
PF-07062119 (0)
PF-07260437 (0)
PIT565 (0)
QLS31904 (0)
QLS31905 (0)
QLS32015 (0)
REGN5459 (0)
RG6007 (0)
RG6129 (0)
RG6232 (0)
RG6286 (0)
RG6353 (0)
RG6524 (0)
RGV004 (0)
catumaxomab (0)
SAIL66 (0)
SAR440234 (0)
TAK-186 (0)
TQB2825 (0)
TQB2934 (0)
UMG2-CD3 BTCE (0)
Undisclosed HER2Bi-armed ATC (0)
WVT078 (0)
XmAb968 (0)
Y150 (0)
ZG006 (0)
AMG 160 (0)
activated CIK and bispecific antibody (0)
activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)
ARB202 (0)
RG6160 (0)
RG7802 (0)
AMG 330 (0)
AMG 673 (0)
GNC-038 (0)
AMG 596 (0)
RG6234 (0)
AMG 910 (0)
huCD33-BsAb (0)
REGN5458 (0)
GD2xCD3 (0)
MGD009 (0)
AMG 420 (0)
XmAb13676 (0)
JNJ-8780 (0)
RG6194 (0)
AMG 110 (0)
MCLA-117 (0)
XmAb18087 (0)
AMG 199 (0)
pegylated interferon α -2a (3)
nadofaragene firadenovec-vncg (1)
interferon alfa 2b (0)
JZP898 (0)
recombinant interferon alfa-2a (0)
SAR441000 (0)
Autologous CD34+ enriched HSPCs expressing interferon-alpha 2 (0)
peginterferon-α-2b (0)
IGN002 (0)
TAK-573 (0)
AAA614 (2)
177Lu-DOTA-EB-FAPI (0)
177Lu-LNC1004 (0)
BI 765179 (0)
MP0310 (0)
MP0317 (0)
RG7827 (0)
SHR-7367 (0)
[177Lu]FAPI-46 (0)
RG7461 (0)
BXCL701 (0)
›
Associations
News
Trials
Filter by
Latest
11ms
MOAT: A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov)
P1, N=36, Recruiting, Akamis Bio | Trial completion date: Dec 2023 --> Oct 2024 | Trial primary completion date: Aug 2023 --> Sep 2024
11 months ago
Trial completion date • Trial primary completion date • Combination therapy
|
Keytruda (pembrolizumab) • NG-641
11ms
NEBULA: Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (clinicaltrials.gov)
P1a/1b, N=30, Recruiting, Akamis Bio | Trial completion date: Dec 2022 --> Jul 2024 | Trial primary completion date: Oct 2022 --> May 2024
11 months ago
Trial completion date • Trial primary completion date • Combination therapy • Metastases • Viral vector
|
Opdivo (nivolumab) • NG-641
2years
NEBULA: Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (clinicaltrials.gov)
P1a/1b, N=30, Recruiting, PsiOxus Therapeutics Ltd | Not yet recruiting --> Recruiting
2 years ago
Enrollment open • Combination therapy
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Opdivo (nivolumab) • NG-641
over2years
NEBULA: Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (clinicaltrials.gov)
P1a/1b, N=30, Not yet recruiting, PsiOxus Therapeutics Ltd
over 2 years ago
Clinical • New P1 trial • Combination therapy
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Opdivo (nivolumab) • NG-641
3years
MOAT: A Dose-escalating, Phase Ib Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov)
P1, N=48, Not yet recruiting, PsiOxus Therapeutics Ltd
3 years ago
New P1 trial
|
LIPI (Lipase I)
|
Keytruda (pembrolizumab) • NG-641
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login